References

Aessopos, A., M. Kati and M. Tsironi, 2008. Congestive heart failure and treatment in thalassemia major. Hemoglobin, 32: 63-73.
PubMed  |  

Aessopos, A., M. Katim and D. Farmakis, 2007. Heart disease in thalassemia intermedia: A review of the underlying pathophysiology. Haematologica, 92: 658-665.
CrossRef  |  

Amer, J., A. Goldfarb and E. Fibach, 2004. Flow cytometric analysis of the oxidative status of normal and thalassemic red blood cells. Cytometry Part A, 60: 73-80.
CrossRef  |  Direct Link  |  

Borgna-Pignatti, C., F. Rigon and L. Merlo, 2003. Thalassemia minor, the Gilbert mutation and the risk of gallstones. Haematologica, 88: 1106-1109.

Cheymol, G., J.M. Poirier, P.A. Carrupt, B. Testa, J. Weissenburger, J.C. Levron and E. Snoeck, 1997. Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. Br. J. Clin. Pharmacol., 43: 563-570.
PubMed  |  

Fucharoen, S., P. Ketvichit and P. Pootrakul , N. Siritanaratkul, A. Piankijagumn and P. Wasi, 2000. Clinical manifestation of beta-thalassemia hemoglobin E disease. J. Pediatr. Hematol. Oncol., 22: 552-557.
PubMed  |  

Galanello, R. and R. Origa, 2010. Beta-thalassemia. Orphanet J. Rare Dis., 5: 11-11.
CrossRef  |  PubMed  |  

Jean, G., S. Terzoli and R. Mauri, 1984. Cirrosis associated with multiple transfusions in thalassemia. Arch. Dis. Child., 59: 67-70.

Lekawanvijit, S. and N. Chattipakorn, 2009. Iron overload thalassemic cardiomyopathy: Iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity. Can. J. Cardiol., 25: 213-218.
PubMed  |  

Ludden, L.M., 1991. Nonlinear pharmacokinetics: Clinical implications. Clin. Pharmacokinet., 20: 429-446.
PubMed  |  

Premawardhena, A., C.A. Fisher and F. Fathiu, 2001. Genetic determinants of jaundice and gallstones in haemoglobin E beta thalassemia. Lancet, 357: 1945-1946.

Rachmilewitz, E.A., S.B. Shohet and B.H. Lubin, 1976. Lipid membrane peroxidation in beta-thalassemia major. Blood, 47: 495-505.
PubMed  |  

Rees, D.C., L. Styles and E.P. Vichinsky, J.B. Clegg and D.J. Weatherall, 1998. The hemoglobin E syndromes. Ann. Acad. Sci., 850: 334-343.
PubMed  |  

Saito, Y., K. Sai, K. Maekawa, N. Kaniwa and K. Shirao et al., 2009. Close association of UGT1A9IVS1+399C>T with UGT1A1*28,*6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug Metab. Dispos., 37: 272-276.
CrossRef  |  

Walker, J.M., 2002. The heart in thalassaemia. Eur. Heart J., 23 : 102-105.

Watson, R.G., W. Bastain, K.A. Larkin, J.R. Hayes, J.A. McAinsh and R.G. Shanks, 1987. A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls. Br. J. Clin. Pharmacol., 24: 527-535.
Direct Link  |  

Weisiger, R.A., J.D. Ostrow, R.K. Koehler, C.C. Webster, P. Mukerjee, L. Pascolo and C. Tiribelli, 2001. Affinity of human serum albumin for bilirubin varies with albumin concentration and buffer composition: Results of a novel ultrafiltration method. J. Biol. Chem., 276: 29953-29960.
CrossRef  |  

Wojcicki, J., M. Jaroszynska and M. Drozdzik, 2003. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normalipaemic and hyperlipidaemic obese subjects. Drug Dispos., 24: 211-218.

Wood, J.C., 2009. Cardiac complications in thalassemia major. Hemoglobin, 33: S81-S86.
PubMed  |  

Yu, L., M. Qian, Y. Liu and S. Zang, 2010. Stereoselective metabolism of propranolol glucuronidation by human UDP-glucuronosyltransferases 2B7 and 1A9. Chirality, 22: 456-461.